Company Overview and News

0
Sayona Mining identifies lithium potential at Tansim project

2018-07-12 proactiveinvestors.com.au
Sayona Mining Ltd (ASX:SYA) has commenced exploration activities at its 12,000-hectare Tansim lithium project in Quebec, Canada.
SYA DMNXF

0
Sayona Mining to drill lithium targets in world-class Pilgangoora district

2018-07-11 proactiveinvestors.com.au
Sayona Mining Ltd (ASX:SYA) will start drilling spodumene pegmatites next month at the Mallina Lithium Project in the world-class Pilgangoora lithium district of Western Australia.
SYA DMNXF

0
Sayona Mining shares surge on completing environmental studies for Authier Lithium Project

2018-07-05 proactiveinvestors.com.au
Sayona Mining Ltd (ASX:SYA) has successfully completed all of the major environmental studies for its Authier Lithium Project in Quebec, Canada.
SYA DMNXF NMX NMKEF

51
Lithium Junior Miner News For The Month Of June 2018

2018-06-27 seekingalpha
Lithium market news: Joe Lowry significantly raised his new lithium demand forecast to ~800K MT LCE in 2025. Indian State-owned firms mandated to acquire overseas lithium and cobalt.
NI LIT CXO SAV LAXXF LIACF CYDVF AGY PFFOF WML POR ABEPF SQM MLNLF AVLNF AIS.H KDR SYA STLHF WMLLF LNRDY HMGLF PEMIF ABE NGZ LMMFF GXY LRS MNIKF PLU HNR AMLM 9984 AVL ALB DMNXF MALRY EEYMF SFTBF MIN NMKEF ARYMF LKE DDXFF MGXMF PLUUF DJIFF NMX PSC EMH CRECF ERPNF SFTBY PLS NNO DJI PDDTF NTTHF NNOMF CYP MALRF ORE AVZ AJM

1
Sayona Mining nears completion of DFS for Authier Lithium Project

2018-06-26 proactiveinvestors.com.au
Sayona Mining Ltd (ASX:SYA) is nearing completion of a definitive feasibility study (DFS) which is expected to lead to development of the Authier Lithium Project in Quebec, Canada.
SYA DMNXF

1
Sayona Mining begins test program to produce lithium carbonate in Canada

2018-06-18 proactiveinvestors.com.au
Sayona Mining Ltd (ASX:SYA) has commenced a testing program in Canada to produce lithium carbonate and lithium hydroxide from the Authier pilot plant lithium concentrate.
SYA DMNXF

1
Sayona Mining directors buys shares under renounceable rights issue

2018-06-01 proactiveinvestors.com.au
Sayona Mining Ltd (ASX:SYA) has had its shares purchased under a renounceable rights issue by its directors.
SYA DMNXF

0
Tesla Sees An Undersupply Of Lithium, But Why Don't You?

2018-05-29 seekingalpha
The SQM-CORFO deal of January, and the subsequent Morgan Stanley report that references the deal (which forecasts lithium oversupply beginning in 2019), was enough to put the lithium sector into hibernation. Since January, lithium stocks have suffered huge losses because of the fear of oversupply.
ALB SYA DMNXF MS.PRE MS.PRF MS.PRG MS.PRA RRSSF GALXF GXY MS.PRI ALTAF TSLA CRECF

1
Sayona Mining secures funding as it closes rights issue

2018-05-29 proactiveinvestors.com.au
Sayona Mining Ltd (ASX:SYA) received applications in its recently closed 1:22 rights issue for $1.146 million worth of shares.
SYA DMNXF

1
Sayona Mining finalises lithium processing flow sheet after completing pilot program

2018-05-22 proactiveinvestors.com.au
Sayona Mining Ltd (ASX:SYA) has completed the operation of its pilot plant program in Canada in preparation for completion of a definitive feasibility study (DFS).
SYA DMNXF

1
Sayona Mining raising up to $4 million in rights offer to support lithium strategy

2018-05-06 proactiveinvestors.com.au
Sayona Mining Ltd (ASX:SYA) intends to raise almost $4 million in an entitlement issue to eligible shareholders to advance its lithium development strategy in Canada.
SYA DMNXF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:SYA / SAYONA MINING LIMITED on message board site Silicon Investor.

PHSYA, Parallell Universe